State and federal class actions

King Pharmaceuticals, Inc

Our attorneys are defending King Pharmaceuticals in several federal and state class actions alleging that manufacturer conspired with a potential generic entrant to delay or block generic entry in violation of Section 1 of the Sherman Act and certain state antitrust, unfair trade practices, and related laws. Our lawyers defeated motions for class certification by plaintiffs seeking to represent classes of indirect purchasers for resale (e.g., pharmacies) and end payor indirect purchasers (e.g., health insurers, pharmacy benefit managers, consumers), as well as successfully resolved the remaining “opt-out” plaintiffs cases. The firm is currently defending related actions in state court.

Email Disclaimer